Summit Recognises C. difficile Awareness Month
November 01, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Recognises C. difficile Awareness Month Oxford, UK, and Cambridge, MA, US, 1 November 2018 – Summit Therapeutics plc (NASDAQ:...
Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
October 03, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018 Ridinilazole in Development to Treat C. difficile Infection and...
Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
September 26, 2018 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week...
Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
August 16, 2018 07:00 ET
|
Summit Therapeutics plc
Brings Total Committed Funding Under BARDA Contract to $44 Million OXFORD, United Kingdom and CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT, AIM:SUMM), a...
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
August 02, 2018 14:00 ET
|
Summit Therapeutics plc
Microbiome Damage Caused by Current Treatments May Lead to Disease RecurrenceRidinilazole Reduced Recurrence Rates by 59% versus Standard of Care Vancomycin OXFORD, U.K. and CAMBRIDGE, Mass., Aug. ...
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
December 21, 2017 02:00 ET
|
Summit Therapeutics plc
Summit to receive $2.5 million upfront paymentUp to $25 million in development, regulatory, pricing and initial sales milestonesSummit retains commercial rights to ridinilazole in rest of the world ...
Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole
November 06, 2017 09:29 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
October 09, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. difficile Infection
September 11, 2017 07:00 ET
|
Summit Therapeutics PLC
CAMBRIDGE, Mass. and OXFORD, United Kingdom, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for...
Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI
September 05, 2017 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...